PEV3A

Identification

Generic Name: PEV3A
DrugBank Accession Number: DB05144
Background: PEV3A is a prophylactic malaria vaccine that acts against various stages of the disease. It is a two-component vaccine that contains the virosome formulated peptide mimetics PEV301 and PEV302. The two synthetic peptide vaccine components mimic the native structure of important antigens of the malaria parasite. The elicited antibodies are highly specific and able to inhibit the parasite’s ability to invade liver tissue in vitro.
Type: Biotech
Groups: Investigational
Biologic Classification: Vaccines
Other vaccines
Synonyms: Not Available

Pharmacology

Indication: Investigated for use/treatment in malaria.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings: Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half-life: Not Available
Clearance: Not Available
Adverse Effects: Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
Abatacept	The therapeutic efficacy of PEV3A can be decreased when used in combination with Abatacept.
Adalimumab	The therapeutic efficacy of PEV3A can be decreased when used in combination with Adalimumab.
Aldesleukin	The therapeutic efficacy of PEV3A can be decreased when used in combination with Aldesleukin.
Alefacept	The therapeutic efficacy of PEV3A can be decreased when used in combination with Alefacept.
Alemtuzumab	The therapeutic efficacy of PEV3A can be decreased when used in combination with Alemtuzumab.

Food Interactions

Not Available

Chemical Identifiers

UNII: Not Available
CAS number: Not Available

References

General References

Not Available

External Links

PubChem Substance: 347909976

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1, 2	Completed	Prevention	Malaria / Malaria caused by Plasmodium falciparum	1

Pharmacoeconomics

Manufacturers: Not Available
Packagers: Not Available
Dosage Forms: Not Available
Prices: Not Available
Patents: Not Available

Properties

State: Solid
Experimental Properties: Not Available

Drug created at October 21, 2007 22:23 / Updated at June 12, 2020 16:52